Malignant transformation by oncogenic K‐ras requires IDH2‐mediated reductive carboxylation to promote glutamine utilization
Rui Liu,
Panpan Liu,
Huichang Bi,
Jianhua Ling,
Huiqin Zhang,
Mingquan Zhang,
Yumin Hu,
Paul J Chiao,
Peng Huang,
Jinyun Liu
Affiliations
Rui Liu
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Panpan Liu
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Huichang Bi
School of Pharmaceutical Sciences Southern Medical University Guangzhou Guangdong 510515 P. R. China
Jianhua Ling
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center Houston Texas 77030 USA
Huiqin Zhang
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Mingquan Zhang
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Yumin Hu
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Paul J Chiao
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center Houston Texas 77030 USA
Peng Huang
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
Jinyun Liu
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong 510060 P. R. China
